Cancer prevalence in Northern Europe: The EUROPREVAL study

T. Möller; H. Anderson; T. Aareleid; T. Hakulinen; H. Storm; L. Tryggvadottir; I. Corazziari; E. Mugno; W. Oberaigner; G. Engholm; G. Hédelin; H. Lefevre; J. Mace-Lesec'h; J. Faivre; G. Chaplain; P. M. Carli; P. Arveux; J. Estève; M. Colonna; N. Raverdy; P. Jun; J. Michaelis; H. Ziegler; C. Stegmaier; R. Capocaccia; R. De Angelis; S. Francisci; S. Hartley; F. Valente; A. Verdecchia; A. Zappone; F. Berrino; G. Gatta; A. Micheli; M. Sant; P. Crosignani; E. Conti; M. Vercelli; C. Casella; A. Puppo; M. Federico; M. Ponz De Leon; V. De Lisi; R. Zanetti; C. Magnani; L. Gafà; F. Falcini; E. Paci; E. Crocetti; S. Guzzinati; J. Rachtan; M. Bielska-Lasota; I. Plesko; V. Pompe-Kirn; I. Izarzugaza; A. Izquierdo; C. Martinez-Garcia; I. Garau; E. Ardanaz; C. Moreno; J. Galceran; V. Moreno; J. Torhorst; C. Bouchardy; J. M. Lutz; M. Usel; J. E. Dowd; J. W.W. Coebergh; M. Janssen-Heijnen; R. A.M. Damuhis; R. Black; V. Harris; D. Stockton; T. W. Davies; M. P. Coleman; S. Harris; E. M.I. Williams; D. Forman; R. Iddenden; M. J. Quinn; M. Roche; J. Smith; H. Moller; P. Silcocks; G. Lawrence; K. Hemmings

doi:10.1093/annonc/mdg255

Cancer prevalence in Northern Europe: The EUROPREVAL study

T. Möller^*, H. Anderson, T. Aareleid, T. Hakulinen, H. Storm, L. Tryggvadottir, I. Corazziari, E. Mugno, W. Oberaigner, G. Engholm, G. Hédelin, H. Lefevre, J. Mace-Lesec'h, J. Faivre, G. Chaplain, P. M. Carli, P. Arveux, J. Estève, M. Colonna, N. RaverdyP. Jun, J. Michaelis, H. Ziegler, C. Stegmaier, R. Capocaccia, R. De Angelis, S. Francisci, S. Hartley, F. Valente, A. Verdecchia, A. Zappone, F. Berrino, G. Gatta, A. Micheli, M. Sant, P. Crosignani, E. Conti, M. Vercelli, C. Casella, A. Puppo, M. Federico, M. Ponz De Leon, V. De Lisi, R. Zanetti, C. Magnani, L. Gafà, F. Falcini, E. Paci, E. Crocetti, S. Guzzinati, J. Rachtan, M. Bielska-Lasota, I. Plesko, V. Pompe-Kirn, I. Izarzugaza, A. Izquierdo, C. Martinez-Garcia, I. Garau, E. Ardanaz, C. Moreno, J. Galceran, V. Moreno, J. Torhorst, C. Bouchardy, J. M. Lutz, M. Usel, J. E. Dowd, J. W.W. Coebergh, M. Janssen-Heijnen, R. A.M. Damuhis, R. Black, V. Harris, D. Stockton, T. W. Davies, M. P. Coleman, S. Harris, E. M.I. Williams, D. Forman, R. Iddenden, M. J. Quinn, M. Roche, J. Smith, H. Moller, P. Silcocks, G. Lawrence, K. Hemmings

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Background: Information on cancer prevalence is of importance for health planning and resource allocation, but is not always available. In order to obtain such data in a comparable way a systematic evaluation of cancer prevalence in Europe was undertaken within the EUROPREVAL project. Patients and methods: Standardised data were collected from 38 population-based registries on almost 3 million cancer patients diagnosed between 1970 and 1992. The prevalence of 11 specific cancer types was estimated at the index date of 31 December 1992. This study deals with the northern countries Denmark, Estonia, Finland, Iceland and Sweden. Results: There were large differences between these countries, Sweden having the highest prevalence rate of 3050 per 100 000 and Estonia the lowest, 1339 per 100 000. This difference is mainly due to a high proportion of cancers with favourable prognosis such as breast cancer, prostate cancer and melanoma, better survival and longer life expectancy in Sweden, whereas Estonia has a higher proportion of stomach and lung cancer with poor prognosis, worse survival and much shorter life expectancy, especially for males. For most tumour types, the Nordic countries did better than Estonia. There are indications that cancer patients in Estonia, as well as in Denmark, have a more advanced stage at diagnosis and that the Estonian health-care system is less efficient. Conclusions: Despite many similarities and a common historical background, the northern countries in Europe that participated in the EUROPREVAL study display quite different cancer patterns and prevalence. Reasons for these variations are discussed.

Original language	English
Pages (from-to)	946-957
Number of pages	12
Journal	Annals of Oncology
Volume	14
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdg255
Publication status	Published - 1 Jun 2003

Keywords

Cancer
EUROPREVAL study
Incidence
Northern Europe
Prevalence
Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdg255

Cite this

Möller, T., Anderson, H., Aareleid, T., Hakulinen, T., Storm, H., Tryggvadottir, L., Corazziari, I., Mugno, E., Oberaigner, W., Engholm, G., Hédelin, G., Lefevre, H., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. M., Arveux, P., Estève, J., Colonna, M., ... Hemmings, K. (2003). Cancer prevalence in Northern Europe: The EUROPREVAL study. Annals of Oncology, 14(6), 946-957. https://doi.org/10.1093/annonc/mdg255

@article{6292a1b10d2e4a11959007fc228fcb7d,

title = "Cancer prevalence in Northern Europe: The EUROPREVAL study",

abstract = "Background: Information on cancer prevalence is of importance for health planning and resource allocation, but is not always available. In order to obtain such data in a comparable way a systematic evaluation of cancer prevalence in Europe was undertaken within the EUROPREVAL project. Patients and methods: Standardised data were collected from 38 population-based registries on almost 3 million cancer patients diagnosed between 1970 and 1992. The prevalence of 11 specific cancer types was estimated at the index date of 31 December 1992. This study deals with the northern countries Denmark, Estonia, Finland, Iceland and Sweden. Results: There were large differences between these countries, Sweden having the highest prevalence rate of 3050 per 100 000 and Estonia the lowest, 1339 per 100 000. This difference is mainly due to a high proportion of cancers with favourable prognosis such as breast cancer, prostate cancer and melanoma, better survival and longer life expectancy in Sweden, whereas Estonia has a higher proportion of stomach and lung cancer with poor prognosis, worse survival and much shorter life expectancy, especially for males. For most tumour types, the Nordic countries did better than Estonia. There are indications that cancer patients in Estonia, as well as in Denmark, have a more advanced stage at diagnosis and that the Estonian health-care system is less efficient. Conclusions: Despite many similarities and a common historical background, the northern countries in Europe that participated in the EUROPREVAL study display quite different cancer patterns and prevalence. Reasons for these variations are discussed.",

keywords = "Cancer, EUROPREVAL study, Incidence, Northern Europe, Prevalence, Survival",

author = "T. M{\"o}ller and H. Anderson and T. Aareleid and T. Hakulinen and H. Storm and L. Tryggvadottir and I. Corazziari and E. Mugno and W. Oberaigner and G. Engholm and G. H{\'e}delin and H. Lefevre and J. Mace-Lesec'h and J. Faivre and G. Chaplain and Carli, {P. M.} and P. Arveux and J. Est{\`e}ve and M. Colonna and N. Raverdy and P. Jun and J. Michaelis and H. Ziegler and C. Stegmaier and R. Capocaccia and {De Angelis}, R. and S. Francisci and S. Hartley and F. Valente and A. Verdecchia and A. Zappone and F. Berrino and G. Gatta and A. Micheli and M. Sant and P. Crosignani and E. Conti and M. Vercelli and C. Casella and A. Puppo and M. Federico and {Ponz De Leon}, M. and {De Lisi}, V. and R. Zanetti and C. Magnani and L. Gaf{\`a} and F. Falcini and E. Paci and E. Crocetti and S. Guzzinati and J. Rachtan and M. Bielska-Lasota and I. Plesko and V. Pompe-Kirn and I. Izarzugaza and A. Izquierdo and C. Martinez-Garcia and I. Garau and E. Ardanaz and C. Moreno and J. Galceran and V. Moreno and J. Torhorst and C. Bouchardy and Lutz, {J. M.} and M. Usel and Dowd, {J. E.} and Coebergh, {J. W.W.} and M. Janssen-Heijnen and Damuhis, {R. A.M.} and R. Black and V. Harris and D. Stockton and Davies, {T. W.} and Coleman, {M. P.} and S. Harris and Williams, {E. M.I.} and D. Forman and R. Iddenden and Quinn, {M. J.} and M. Roche and J. Smith and H. Moller and P. Silcocks and G. Lawrence and K. Hemmings",

year = "2003",

month = jun,

day = "1",

doi = "10.1093/annonc/mdg255",

language = "English",

volume = "14",

pages = "946--957",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "6",

}

Möller, T, Anderson, H, Aareleid, T, Hakulinen, T, Storm, H, Tryggvadottir, L, Corazziari, I, Mugno, E, Oberaigner, W, Engholm, G, Hédelin, G, Lefevre, H, Mace-Lesec'h, J, Faivre, J, Chaplain, G, Carli, PM, Arveux, P, Estève, J, Colonna, M, Raverdy, N, Jun, P, Michaelis, J, Ziegler, H, Stegmaier, C, Capocaccia, R, De Angelis, R, Francisci, S, Hartley, S, Valente, F, Verdecchia, A, Zappone, A, Berrino, F, Gatta, G, Micheli, A, Sant, M, Crosignani, P, Conti, E, Vercelli, M, Casella, C, Puppo, A, Federico, M, Ponz De Leon, M, De Lisi, V, Zanetti, R, Magnani, C, Gafà, L, Falcini, F, Paci, E, Crocetti, E, Guzzinati, S, Rachtan, J, Bielska-Lasota, M, Plesko, I, Pompe-Kirn, V, Izarzugaza, I, Izquierdo, A, Martinez-Garcia, C, Garau, I, Ardanaz, E, Moreno, C, Galceran, J, Moreno, V, Torhorst, J, Bouchardy, C, Lutz, JM, Usel, M, Dowd, JE, Coebergh, JWW, Janssen-Heijnen, M, Damuhis, RAM, Black, R, Harris, V, Stockton, D, Davies, TW, Coleman, MP, Harris, S, Williams, EMI, Forman, D, Iddenden, R, Quinn, MJ, Roche, M, Smith, J, Moller, H, Silcocks, P, Lawrence, G & Hemmings, K 2003, 'Cancer prevalence in Northern Europe: The EUROPREVAL study', Annals of Oncology, vol. 14, no. 6, pp. 946-957. https://doi.org/10.1093/annonc/mdg255

TY - JOUR

T1 - Cancer prevalence in Northern Europe

T2 - The EUROPREVAL study

AU - Möller, T.

AU - Anderson, H.

AU - Aareleid, T.

AU - Hakulinen, T.

AU - Storm, H.

AU - Tryggvadottir, L.

AU - Corazziari, I.

AU - Mugno, E.

AU - Oberaigner, W.

AU - Engholm, G.

AU - Hédelin, G.

AU - Lefevre, H.

AU - Mace-Lesec'h, J.

AU - Faivre, J.

AU - Chaplain, G.

AU - Carli, P. M.

AU - Arveux, P.

AU - Estève, J.

AU - Colonna, M.

AU - Raverdy, N.

AU - Jun, P.

AU - Michaelis, J.

AU - Ziegler, H.

AU - Stegmaier, C.

AU - Capocaccia, R.

AU - De Angelis, R.

AU - Francisci, S.

AU - Hartley, S.

AU - Valente, F.

AU - Verdecchia, A.

AU - Zappone, A.

AU - Berrino, F.

AU - Gatta, G.

AU - Micheli, A.

AU - Sant, M.

AU - Crosignani, P.

AU - Conti, E.

AU - Vercelli, M.

AU - Casella, C.

AU - Puppo, A.

AU - Federico, M.

AU - Ponz De Leon, M.

AU - De Lisi, V.

AU - Zanetti, R.

AU - Magnani, C.

AU - Gafà, L.

AU - Falcini, F.

AU - Paci, E.

AU - Crocetti, E.

AU - Guzzinati, S.

AU - Rachtan, J.

AU - Bielska-Lasota, M.

AU - Plesko, I.

AU - Pompe-Kirn, V.

AU - Izarzugaza, I.

AU - Izquierdo, A.

AU - Martinez-Garcia, C.

AU - Garau, I.

AU - Ardanaz, E.

AU - Moreno, C.

AU - Galceran, J.

AU - Moreno, V.

AU - Torhorst, J.

AU - Bouchardy, C.

AU - Lutz, J. M.

AU - Usel, M.

AU - Dowd, J. E.

AU - Coebergh, J. W.W.

AU - Janssen-Heijnen, M.

AU - Damuhis, R. A.M.

AU - Black, R.

AU - Harris, V.

AU - Stockton, D.

AU - Davies, T. W.

AU - Coleman, M. P.

AU - Harris, S.

AU - Williams, E. M.I.

AU - Forman, D.

AU - Iddenden, R.

AU - Quinn, M. J.

AU - Roche, M.

AU - Smith, J.

AU - Moller, H.

AU - Silcocks, P.

AU - Lawrence, G.

AU - Hemmings, K.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background: Information on cancer prevalence is of importance for health planning and resource allocation, but is not always available. In order to obtain such data in a comparable way a systematic evaluation of cancer prevalence in Europe was undertaken within the EUROPREVAL project. Patients and methods: Standardised data were collected from 38 population-based registries on almost 3 million cancer patients diagnosed between 1970 and 1992. The prevalence of 11 specific cancer types was estimated at the index date of 31 December 1992. This study deals with the northern countries Denmark, Estonia, Finland, Iceland and Sweden. Results: There were large differences between these countries, Sweden having the highest prevalence rate of 3050 per 100 000 and Estonia the lowest, 1339 per 100 000. This difference is mainly due to a high proportion of cancers with favourable prognosis such as breast cancer, prostate cancer and melanoma, better survival and longer life expectancy in Sweden, whereas Estonia has a higher proportion of stomach and lung cancer with poor prognosis, worse survival and much shorter life expectancy, especially for males. For most tumour types, the Nordic countries did better than Estonia. There are indications that cancer patients in Estonia, as well as in Denmark, have a more advanced stage at diagnosis and that the Estonian health-care system is less efficient. Conclusions: Despite many similarities and a common historical background, the northern countries in Europe that participated in the EUROPREVAL study display quite different cancer patterns and prevalence. Reasons for these variations are discussed.

AB - Background: Information on cancer prevalence is of importance for health planning and resource allocation, but is not always available. In order to obtain such data in a comparable way a systematic evaluation of cancer prevalence in Europe was undertaken within the EUROPREVAL project. Patients and methods: Standardised data were collected from 38 population-based registries on almost 3 million cancer patients diagnosed between 1970 and 1992. The prevalence of 11 specific cancer types was estimated at the index date of 31 December 1992. This study deals with the northern countries Denmark, Estonia, Finland, Iceland and Sweden. Results: There were large differences between these countries, Sweden having the highest prevalence rate of 3050 per 100 000 and Estonia the lowest, 1339 per 100 000. This difference is mainly due to a high proportion of cancers with favourable prognosis such as breast cancer, prostate cancer and melanoma, better survival and longer life expectancy in Sweden, whereas Estonia has a higher proportion of stomach and lung cancer with poor prognosis, worse survival and much shorter life expectancy, especially for males. For most tumour types, the Nordic countries did better than Estonia. There are indications that cancer patients in Estonia, as well as in Denmark, have a more advanced stage at diagnosis and that the Estonian health-care system is less efficient. Conclusions: Despite many similarities and a common historical background, the northern countries in Europe that participated in the EUROPREVAL study display quite different cancer patterns and prevalence. Reasons for these variations are discussed.

KW - Cancer

KW - EUROPREVAL study

KW - Incidence

KW - Northern Europe

KW - Prevalence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=17744410787&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg255

DO - 10.1093/annonc/mdg255

M3 - Article

C2 - 12796034

AN - SCOPUS:17744410787

SN - 0923-7534

VL - 14

SP - 946

EP - 957

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -

Cancer prevalence in Northern Europe: The EUROPREVAL study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this